NAGE (STOCKS)
Niagen Bioscience, Inc. Common Stock
$4.640000
+0.140000 (+3.11%)
Prev close: $4.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Robert N. Fried
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $368.77M
- Employees
- 104
- P/E (TTM)
- 22.12
- P/B (TTM)
- 4.69
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.03 | $0.02 | +0.0076 | +33.93% |
|
Sep 2025 (Q3)
|
$0.05 | $0.02 | +0.0337 | +206.75% |
|
Jun 2025 (Q2)
|
$0.04 | $0.01 | +0.0257 | +179.72% |
|
Mar 2025 (Q1)
|
$0.06 | $0.02 | +0.0430 | +252.94% |
Financial Statements
| Revenues | $129.42M |
| Benefits Costs and Expenses | $111.23M |
| Cost Of Revenue | $46.23M |
| Costs And Expenses | $111.23M |
| Gross Profit | $83.19M |
| Operating Expenses | $66.91M |
| Research and Development | $6.33M |
| Other Operating Expenses | $60.58M |
| Operating Income/Loss | $16.28M |
| Income/Loss From Continuing Operations After Tax | $17.38M |
| Income/Loss From Continuing Operations Before Tax | $18.19M |
| Income Tax Expense/Benefit | $810.00K |
| Income Tax Expense/Benefit, Current | $810.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | $17.38M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $17.38M |
| Net Income/Loss Available To Common Stockholders, Basic | $17.38M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.22 |
| Diluted Earnings Per Share | $0.20 |
| Basic Average Shares | 79,178,000 |
| Diluted Average Shares | 85,436,000 |
| Assets | $106.41M |
| Current Assets | $96.81M |
| Noncurrent Assets | $9.60M |
| Intangible Assets | $5.66M |
| Other Non-current Assets | $3.94M |
| Liabilities | $29.87M |
| Current Liabilities | $19.92M |
| Accounts Payable | $10.80M |
| Other Current Liabilities | $9.12M |
| Noncurrent Liabilities | $9.95M |
| Equity | $76.53M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $76.53M |
| Liabilities And Equity | $106.41M |
| Net Cash Flow From Operating Activities | $13.50M |
| Net Cash Flow From Operating Activities, Continuing | $13.50M |
| Net Cash Flow From Investing Activities | -$292.00K |
| Net Cash Flow From Investing Activities, Continuing | -$292.00K |
| Net Cash Flow From Financing Activities | $6.92M |
| Net Cash Flow From Financing Activities, Continuing | $6.92M |
| Net Cash Flow | $20.13M |
| Net Cash Flow, Continuing | $20.13M |
| Comprehensive Income/Loss | $17.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $17.38M |
| Other Comprehensive Income/Loss | $0.00 |